In the Lightning Round, Cramer was bullish on
Cramer was bearish on
New Residential Investment
Who's Next to Be Bought?
, Cramer asked the logical question: "Who's next?" After screening the entire biotech sector, he uncovered three solid prospects.
(MDVN - Get Report)
is the first stock that could be taken over; this company's prostate cancer treatment is showing positive results, with patients surviving an average of 18.4 months longer. Medivation also has a bountiful pipeline of products, making it ripe for the picking.
Next on the list is
(SGEN - Get Report)
, a stock that's already up 68% since Cramer last spoke with the company's CEO in December. Seattle Genetics' targeted cancer treatment, Adcentris, is also proving to be a winner and the company is already working to expand its use to new indications.
Finally, Cramer noted orphan drug maker
(BMRN - Get Report)
as a potential acquisition target. He said this company is easily worth $11 to $12 billion to a potential acquirer.
No Huddle Offense
In his "No Huddle Offense" segment, Cramer responded to recent reports the hydraulic fracturing technology used to produce natural gas is causing earthquakes and tremors in our oil shale regions.
Cramer said these reports need to be monitored and studied closely, but the fact of the matter is all energy sources have side effects. You simply cannot get energy without damage being caused somewhere. Tremors may not be a huge win, he said, but it's certainly less of a loss than importing oil from abroad.
Cramer once again called energy independence a national imperative, one that creates jobs and, in the case of natural gas, is far cleaner than using oil and coal alternatives or driving up food prices with ethanol. So while natural gas may not be perfect, it's certainly the best alternative we have at the moment until renewable fuels become more practical.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
-- Written by Scott Rutt in Washington, D.C.
To email Scott about this article, click here:
Follow Scott on Twitter
or get updates on Facebook,